21 results about "LDL receptor" patented technology

The present disclosure relates to viral glycoprotein variants with reduced (e.g., abolished) binding to low-density lipoprotein receptor (LDL-R) compared to a reference viral glycoprotein. Recombinant viruses pseudotyped with viral glycoprotein variants described herein and optionally an envelope surface-bound targeting molecule (e.g., an anti-CD3 scFv), methods of producing thereof, and methods of using thereof, are also provided.

An aptamer composition is disclosed which has one or more oligonucleotides that include at least one of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, or mixtures thereof. The aptamer composition has a binding affinity for one or more cellular membrane glycoproteins selected from the group consisting of: intercellular adhesion molecule 1 (ICAM-1), low-density lipoprotein receptor (LDLR) family members, and cadherin-related family member 3 (CDHR3), preferably intercellular adhesion molecule 1 (ICAM-1), and is configured to reduce the binding of one or more human rhinoviruses to the intercellular adhesion molecule 1 (ICAM-1).

Compositions and methods for enhancing payload-based gene therapy by blocking binding of LDL to LDL receptor (LDLR) in the liver, and then administering a payload-based therapy targeting non-liver tissue to increase the percentage of payload of non-liver targets delivered to a subject.

The application discloses a method for rapidly and quantitatively determining biological activity of anti-PCSK9 monoclonal antibody drugs, and is based on HepG2 liver cancer cells, and utilizes the principle that specific binding of a series of concentration gradient PCSK9 monoclonal antibodies to a certain concentration of PCSK9 protein indirectly causes a dose response of DiI-LDL absorption to LDL receptors on the surface of liver cells, so that a biological activity detection method of the PCSK9 monoclonal antibody drugs is preliminarily established, and methodological verification proves that the method has strong specificity, good accuracy and high precision, and can be used for release detection of products, and has important significance for process control in a production process and drug quality control.

The present invention relates to NK cells expressing dual-targeting chimeric antigen receptors for CD19 and CD22, and uses thereof. In the present invention, it was found that the delivery efficiency of a CAR expression vector and the production efficiency of CAR-NK cells are excellent when, among the cell surface proteins of PBMCs for producing CAR-NK cells (UCI-101), CD16 is expressed at 70% or less, natural killer group 2D (NKG2D) is expressed at less than 10%, CD57 is expressed at 30% or less, low-density lipoprotein receptor (LDLR) is expressed at 0.1% or more, and natural cytotoxicity triggering receptor 3 (NKp30) is expressed at less than 10%. In addition, optimal conditions for inducing NK cell differentiation and optimal conditions for transduction, under which the delivery efficiency of a CAR expression vector and the production efficiency of CAR-NK cells are excellent, were established, and CAR-NK cells produced by the method according to the present invention were found to exhibit an excellent antitumor effect in an animal model, and thus can be effectively used as a composition for preventing or treating diseases related to CD22 (or CD19) expression or diseases related to B cells.

The application belongs to the technical field of diagnostic markers, and particularly relates to a pathological diagnosis biomarker combination for adrenal Cushing syndrome and application. The pathological diagnosis biomarker combination comprises low density lipoprotein receptor (LDLR), 3-hydroxy-3-methylglutaryl coenzyme A synthetase 1 (HMGCS1) and cytochrome P450 11B1 (CYP11B1). The area under the ROC curve (AUC) of the pathological diagnosis biomarker combination can reach 0.881 (95% confidence interval (CI): 0.775-987; sensitivity: 85.7%; specificity: 85.0%), which indicates that the combination of LDLR, HMGCS1 and CYP11B1 as the pathological diagnosis biomarker combination for adrenal Cushing syndrome has high accuracy.

An aptamer composition is disclosed which has one or more oligonucleotides that include at least one of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, or mixtures thereof. The aptamer composition has a binding affinity for one or more cellular membrane glycoproteins selected from the group consisting of: intercellular adhesion molecule 1 (ICAM-1), low-density lipoprotein receptor (LDLR) family members, and cadherin-related family member 3 (CDHR3), preferably intercellular adhesion molecule 1 (ICAM-1), and is configured to reduce the binding of one or more human rhinoviruses to the intercellular adhesion molecule 1 (ICAM-1).

The invention belongs to the fields of biochemistry, genetic engineering, structural biology and protein engineering, and particularly relates to a low-density lipoprotein receptor-like protein NvLRP expressed in Nacoia vitripennis as well as a nucleotide sequence coded by the low-density lipoprotein receptor-like protein NvLRP and a function of the low-density lipoprotein receptor-like protein NvLRP. The invention provides a low-density lipoprotein receptor-like protein (NvLRP) of chrysalis rivularis. The NvLRP has an amino acid sequence as shown in SEQ ID NO: 2. The NvLRP protein provided by the invention has a remarkable agglutination effect on blood cells of boettcherisca peregrina, affects the immune response of the boettcherisca peregrina, and has insecticidal potential.

Methods for identifying chronic hydrocephalus include assaying for an amount in a biological sample of one or more biomarkers selected from pyruvate dehydrogenase lipoamide kinase isozyme 4 (PDK4), phosphofructokinase-muscle (PFKM), low density lipoprotein receptor adaptor protein 1 (LDLRAP1), glucagon-like peptide-1 receptor (GLP-1R), hemoglobin subunit alpha 1 (HBA1), hemoglobin subunit alpha 2 (HBA2), heme oxygenase 1 (HMOX1), and combinations thereof. Methods for screening for a compound useful for treating chronic hydrocephalus are also provided and include contacting a cell with an effective amount of a test compound, and then detecting an expression or activity level of one or more of the biomarkers.

Provided herein, among other things, are novel and improved glycoproteins, including modified glycoproteins; engineered viral particles comprising such novel and modified glycoproteins; and methods for targeted delivery, for example, to immune cells such as T cells. In some aspects, the engineered viral particles allow targeted delivery of the cargo for various applications, including treating various conditions such as autoimmune diseases and cancer. In some aspects, the engineered viral particles comprise a viral fusogen that is a glycoprotein of Chandipura, Perinet, Piry, Jurona viruses, or variants thereof. In other aspects, the engineered viral particles comprise a modified vesiculovirus glycoprotein mutant, for example, with mutations at amino acids corresponding to positions I347 or R354 of Vesicular Stomatitis Virus G (VSV-G) that reduce binding to Low Density Lipoprotein Receptor (LDL-R).

The invention relates to the technical field of biological medicine, in particular to a lysosome sorting signal-nucleic acid aptamer chimera as well as a preparation method and application thereof. The lysosome sorting signal-nucleic acid aptamer chimera comprises a first sequence and a second sequence, and the first sequence and the second sequence are coupled through a click chemical reaction; wherein the first sequence comprises a nucleic acid aptamer selectively combined with target protein, and the second sequence comprises a polypeptide sequence containing a low-density lipoprotein receptor NPXY motif. The lysosome sorting signal-nucleic acid aptamer chimera disclosed by the invention has the characteristics of simultaneously targeting a target protein and a lysosome, can be specifically combined with the target protein to be degraded, and transports the target protein to the lysosome for degradation, so that the specific and efficient degradation of the target protein can be realized.

Compositions and methods for treating urinary tract infection (UTI) and / or sepsis in a subject in need thereof are provided. Methods include administering to the subject a composition comprising an alpha-hemolysin (HlyA) inhibiting agent. In some embodiments, the HlyA inhibiting agent includes a soluble low-density lipoprotein receptor (LDLR)-Fc fusion protein as described herein, a clathrin-mediated endocytosis (CME) inhibitor, and / or an anti-LDLR antibody. In some embodiments, the soluble LDLR-Fc fusion protein includes an Fc domain and at least one LDLR type A domain. In some embodiments, the UTI and / or sepsis is caused by E. coli.

Methods and assays for identifying Alzheimer's disease in a subject include determining an amount in the biological sample of one or more biomarkers selected from glucagon-like peptide 1 receptor (GLP-1R), C2 calcium dependent domain containing 4C (C2CD4C), low-density lipoprotein receptor adapter protein 1 (LDLRAP1), nuclear factor erythroid 2-related factor 2 (NFE2L2), doublecortin (DCX), sequestosome (SQSTM1), nuclear factor κB1 (NFκB1), transcription factor RelB (RelB), and combinations thereof. Methods and assays for identifying chronic hydrocephalus in a subject are also provided and include determining an amount in a biological sample of RelB and / or FCGBP. Screening methods are further provided and include contacting a cell with an effective amount of a test compound and then detecting an expression level or activity of the biomarkers.

The invention relates to a library construction method based on high-throughput sequencing endometrial cancer molecular typing, and relates to the technical field of medical data process.The library construction method includes the steps that a clinical index-molecular feature linked dynamic typing system is established, and sequencing data of peripheral blood LDL concentration and other clinical metabolic indexes and tumor tissue pathway genes are integrated; a multi-dimensional data analysis model is established, double typing of metabolic phenotypes and molecular pathways of endometrial cancer is realized, a basis is provided for matching differentiated treatment schemes for patients with different subtypes, the typing specificity and accuracy are improved, a high-throughput sequencing library of targeted LDL metabolism and JAK / STAT pathway genes is constructed, and a high-throughput sequencing library of targeted LDL metabolism and JAK / STAT pathway genes is established. Nucleic acid fragments of key genes such as JAK2, STAT3 and LDL receptors are enriched through a specific probe, irrelevant nucleic acid interference is eliminated, the detection sensitivity and typing accuracy of LDL-JAK / STAT pathway abnormal endometrial cancer are improved, and the technical blank of special subtype molecular typing is filled.

An aptamer composition is disclosed which has one or more oligonucleotides that include at least one of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, or mixtures thereof. The aptamer composition has a binding affinity for one or more cellular membrane glycoproteins selected from the group consisting of: intercellular adhesion molecule 1 (ICAM-1), low-density lipoprotein receptor (LDLR) family members, and cadherin-related family member 3 (CDHR3), preferably intercellular adhesion molecule 1 (ICAM-1), and is configured to reduce the binding of one or more human rhinoviruses to the intercellular adhesion molecule 1 (ICAM-1).

Provided herein, among other things, are novel and improved glycoproteins, including modified glycoproteins; engineered viral particles comprising such novel and modified glycoproteins; and methods for targeted delivery, for example, to immune cells such as T cells. In some aspects, the engineered viral particles allow targeted delivery of the cargo for various applications, including treating various conditions such as autoimmune diseases and cancer. In some aspects, the engineered viral particles comprise a viral fusogen that is a glycoprotein of Chandipura, Perinet, Piry, Jurona viruses, or variants thereof. In other aspects, the engineered viral particles comprise a modified vesiculovirus glycoprotein mutant, for example, with mutations at amino acids corresponding to positions I347 or R354 of Vesicular Stomatitis Virus G (VSV-G) that reduce binding to Low Density Lipoprotein Receptor (LDL-R).

The invention provides a lentivirus packaging system and a kit and application of the lentivirus packaging system and the kit in pseudotyped packaging and CAR-T cell preparation. The packaging system comprises an enveloping plasmid and a transmembrane targeting plasmid, enveloping protein expressed by the enveloping plasmid is targeted Cocal-G enveloping protein, and the capacity of the original Cocal-G enveloping protein for self-targeting a low-density lipoprotein receptor is removed. The transmembrane region of the transmembrane protein expressed by the transmembrane targeting plasmid is shown as SEQ ID NO: 10, and the lentivirus packaged by the packaging system not only has higher packaging efficiency and activity, but also has clearer and more stable targeting.

Methods and assays for identifying Alzheimer's disease in a subject include determining an amount in the biological sample of one or more biomarkers selected from glucagon-like peptide 1 receptor (GLP-1R), C2 calcium dependent domain containing 4C (C2CD4C), low-density lipoprotein receptor adapter protein 1 (LDLRAP1), nuclear factor erythroid 2-related factor 2 (NFE2L2), doublecortin (DCX), sequestosome (SQSTM1), nuclear factor κB1 (NFκB1), transcription factor RelB (RelB), and combinations thereof. Methods and assays for identifying chronic hydrocephalus in a subject are also provided and include determining an amount in a biological sample of RelB and / or FCGBP. Screening methods are further provided and include contacting a cell with an effective amount of a test compound and then detecting an expression level or activity of the biomarkers.

The present disclosure relates to genome editing systems and components for targeting, editing, and / or modulating the expression of a target nucleic acid sequence of interest, e.g., an LDLR target nucleic acid sequence in the 3' untranslated region (UTR) of the gene encoding the LDLR protein. The present disclosure is also directed to methods and applications thereof in connection with the treatment and / or management of hypercholesterolemia.

Compositions and methods for enhancing payload-based gene therapy by increasing the percentage of payload delivered to a non-liver target in a subject by blocking binding of LDL to LDL receptors (LDLR) in the liver, and then administering a payload-based therapy targeting a non-liver tissue.

Compositions and methods for the prevention or treatment of Crimean-Congo hemorrhagic fever virus (CCHFV) infection, or for the prevention or treatment of Crimean-Congo hemorrhagic fever are provided. The methods comprise administering to a subject infected with or at risk of infection a virus an agent that reduces the expression or activity of LDLR, or inhibits the interaction between low density lipoprotein receptor (LDLR) and Gc glycoprotein (Gc) of CCHFV in the subject.